Skip to main content
Clinical Trials/IRCT20240501061618N1
IRCT20240501061618N1
Recruiting
Phase 2

Investigating the efficacy and safety of Curcumin on the prevention of non-alcoholic fatty liver disease (NAFLD) in patients with non-metastatic breast cancer receiving tamoxifen

Esfahan University of Medical Sciences0 sites44 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Fatty liver caused by tamoxifen in patients with non-metastatic breast cancer.
Sponsor
Esfahan University of Medical Sciences
Enrollment
44
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Women with non\-metastatic breast cancer whose pathology is positive in terms of hormone receptors and are treated with tamoxifen.
  • Normal liver enzymes
  • Not having viral hepatitis
  • Not having a history of alcohol consumption
  • Not using drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs.
  • Insensitivity to curcumin drug
  • No history of chemotherapy

Exclusion Criteria

  • The patient's unwillingness to continue the study
  • Having liver diseases during the study
  • The use of drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs after the start of the study.
  • Suffering from any related disease and distorting the results during the study
  • Allergic to curcumin drug
  • Development of Metastasis during the study

Outcomes

Primary Outcomes

Not specified

Similar Trials